About Evaldo Stanislau

Graduate at Santos School of Medicine (UNILUS) in 1991 with residency in Internal Medicine and Infectious Disease (1992-1996), Master Degree at University of Sao Paulo (2000) and PhD at University of Sao Paulo (2005) being an active physician and researcher in the viral hepatitis field since early years of medical residence. Ministry of Health advisor since 2003 building the Brazilian response against viral hepatitis both in the organization of national care at Secretaria de Atenção a Saude and as a technical advisor for the therapy guidelines since the Interferon Era and specially in the transition for Interferon free therapy at Secretaria de Vigilancia a Saude, DST-Aids/Hepatites department. HCV Guideline Group member at WHO and former Viral Hepatitis STAC member (2014-2016 term). Former coordinator of the hepatitis care in the city of Sao Paulo. Active member and organizer of several NGOs meetings and actions in the fight against viral hepatitis being the founder (1999) of Grupo Esperança one of the more activy NGO in Brazil. Active researcher and author of several articles, chapters, books as well national consensus for Brazilian scientific societies in the viral hepatitis field. Current assistanct-doctor at HC-FMUSP. 

This speaker will be presenting at the following session(s)

  • Policy as a tool for HepC Elimination

    Matisse

    Day: 1 November

    Time: 17:30

    Hepatitis C virus (HCV) infection is considered a major Public Health threat in Europe.

    Hepatitis C virus (HCV) infection is considered a major Public Health threat in Europe. Hepatitis C is a chronic infectious disease with great impact on patients’ morbidity and mortality, with high risk of progression to cirrhosis and liver cancer. In Europe, it is estimated that only 25% of patients with hepatitis C are diagnosed (~14 million people); each year there are 27,000-29,000 newly diagnosed HCV cases in the EU/EEA. Evidence shows that, for some European countries, annual deaths from hepatitis c have quadrupled over the past 20 years. New treatments were recently discovered that cures hepatitis C in up to 97% of cases. This, alongside the devastating effects that the disease can have, means that the paradigm at the community level of hepatitis c treatment should now be elimination.

    Presentations:

    • From policy to action.
      Charles Gore, World Hepatitis Alliance
    • What matters to patients - HepCore.
      Prof. Jeffrey Lazarus, University of Copenhagen
    • Empowering advocates.
      Achim Kautz, Leberhilfe Projekt gUG
    • Modelling for policy change.
      Dr. Homie A. Razavi, Center for Disease Analysis Foundation
    • Brazil strategy and response to HCV.
      Evaldo Stanislau Affonso de Araújo, Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo
    • Let's End HepC Dashboard - assessing and comparing different Countries policies in real-time towards the elimination of HCV until 2030.
      Ricardo Baptista Leite, Member of the Portuguese Parliament and Católica University of Portugal